AXCSSenior Chief Aviation Antisubmarine Warfare Technician (Naval Rating)
References in periodicals archive ?
Because of this announcement, and several recent announcements of advancements of clinical programs (see research update 1/12/99), we continue to believe that AXCS shares, which currently trade OTC, are undervalued.
Conclusion: We continue to believe that AXCS is a technology-rich company with significant potential.
We characterize AXCS as an emerging pharmaceutical company, rather than a traditional biotech company, as we believe its business model has components that are less risky than the typical one-compound, or one-technology-platform, biotech company.